Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Kubota, Takafumi; Kuroda, Naoto

doi:10.1016/j.clineuro.2020.106349

Cited by 76 publications

(73 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The evidence on the susceptibility of PWE to contracting COVID-19 and the consequences of this catastrophic disease in PWE is scarce. A recent systematic review suggested that patients with pre-existing neurological disorders (including epilepsy) and COVID-19 may develop exacerbation of their neurological problems and also severe COVID-19 [72]. This significant concern should be addressed in the future through well-designed prospective cohort studies with all relevant confounders controlled.…”

Section: Discussionmentioning

confidence: 99%

COVID-19, de novo seizures, and epilepsy: a systematic review

et al. 2020

View full text Add to dashboard Cite

Objective We discuss the evidence on the occurrence of de novo seizures in patients with COVID-19, the consequences of this catastrophic disease in people with epilepsy (PWE), and the electroencephalographic (EEG) findings in patients with COVID-19. Methods This systematic review was prepared according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. MEDLINE, Scopus, and Embase from inception to August 15, 2020 were systematically searched. These key words were used: "COVID" AND "seizure" OR "epilepsy" OR "EEG" OR "status epilepticus" OR "electroencephalography". Results We could identify 62 related manuscripts. Many studies were case reports or case series of patients with COVID-19 and seizures. PWE showed more psychological distress than healthy controls. Many cases with new-onset focal seizures, serial seizures, and status epilepticus have been reported in the literature. EEG studies have been significantly ignored and underused globally. Conclusion Many PWE perceived significant disruption in the quality of care to them, and some people reported increase in their seizure frequency since the onset of the pandemic. Telemedicine is a helpful technology that may improve access to the needed care for PWE in these difficult times. De novo seizures may occur in people with COVID-19 and they may happen in a variety of forms. In addition to prolonged EEG monitoring, performing a through metabolic investigation, electrocardiogram, brain imaging, and a careful review of all medications are necessary steps. The susceptibility of PWE to contracting COVID-19 should be investigated further.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19, de novo seizures, and epilepsy: a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although 95.6% of PD patients are taking precautions including handwashing, mask-wearing, rigorous confinement, social distancing, and use of gloves, only 68.8% were concerned about the virus [ 116 ]. However, this population may be at a higher risk of disease severity as 11.7% of PD patients were admitted to the intensive care unit or had severe pneumonia after contracting the virus [ 117 ]. Additionally, these patients are at a higher risk of dying from COVID-19 compared to non-PD patients [ 118 ].…”

Section: Sars-cov-2 Infection Of the Nervous Systemmentioning

confidence: 99%

“…Further, COVID-19 may also exacerbate neurological symptoms in PD patients [ 117 ]. Case reports have described the onset of worsening PD and motor symptoms (i.e., fall, speech disturbance, dystonic spasms) prior to the diagnosis of COVID-19 [ [121] , [122] , [123] ].…”

Section: Sars-cov-2 Infection Of the Nervous Systemmentioning

confidence: 99%

SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders

Amruta

Chastain

Paz

et al. 2021

Cytokine & Growth Factor Reviews

107

View full text Add to dashboard Cite

show abstract

“…Based on the limitations of the first study and the inconclusive results of the second study, it is probably too early to determine that epilepsy is a risk factor for COVID-19. A systematic review article showed that the rate of COVID-19 severity in people with epilepsy is lower than other neurological disorders such as dementia, cerebrovascular disease, and multiple sclerosis [6]. In addition, epilepsy is not a single disease, and has many causes and associations, some of which may debilitate the patient and increase the risk of respiratory or other independent risk factors.…”

Section: Associations Between Covid-19 and Epilepsy/seizurementioning

confidence: 99%

Epilepsy and COVID-19: Updated evidence and narrative review

Kuroda

2021

Epilepsy & Behavior

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) outbreak started in Wuhan, China, in late 2019 and rapidly spread globally. Vaccines have recently been developed and are being administered in some countries, but their widespread use is not yet sufficient; the battle against COVID-19 is protracted and people need to adapt to living under the influence of this disease. Epilepsy is a common chronic neurological condition characterized by spontaneous recurrence of unprovoked seizures. Various effects of COVID-19 on epilepsy have been studied in recent months. As clinicians, we need to keep up with daily updates in the evidence regarding interactions between COVID-19 and epilepsy. This review article summarizes the current evidence. Prospective studies on epilepsy and COVID-19 remain lacking. Most articles have comprised case reports, case series, retrospective studies, and recommendations/opinions that do not include data. However, summarizing these articles can identify the demands for research into COVID-19 and epilepsy by clarifying what is known and what remains unclear from current research.

show abstract

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Cited by 76 publications

References 47 publications

COVID-19, de novo seizures, and epilepsy: a systematic review

COVID-19, de novo seizures, and epilepsy: a systematic review

SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders

Epilepsy and COVID-19: Updated evidence and narrative review

Contact Info

Product

Resources

About